Johnson & Johnson’s Neumora Therapeutics NMRA Stock Holding History

Johnson & Johnson’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.14M	Hold	1,849,445	–	–	0.39%	12
2026 Q1	$3.61M	Hold	1,849,445	–	–	0.55%	11
2025 Q4	$3.31M	Hold	1,849,445	–	–	0.6%	11
2025 Q3	$3.37M	Hold	1,849,445	–	–	0.67%	12
2025 Q2	$1.4M	Hold	1,849,445	–	–	0.42%	12
2025 Q1	$1.85M	Hold	1,849,445	–	–	0.54%	13
2024 Q4	$19.6M	Hold	1,849,445	–	–	5.08%	8
2024 Q3	$24.4M	Hold	1,849,445	–	–	5.72%	9
2024 Q2	$18.2M	Hold	1,849,445	–	–	4.54%	9
2024 Q1	$25.4M	Hold	1,849,445	–	–	0.58%	9
2023 Q4	$31.5M	Buy	1,849,445 +937,317	+103%	+$11.5M	0.72%	9
2023 Q3	$12.9M	Buy	+912,128	New	+$11.4M	4.74%	6

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson's NMRA Position: Q2 2026 in Review

Johnson & Johnson held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 1,849,445 shares worth $3.14M. The position accounts for 0.39% of the portfolio, ranked #12.

Johnson & Johnson first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $31.5M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Johnson & Johnson held 1,849,445 shares of Neumora Therapeutics worth $3.14M as of Q2 2026.
Johnson & Johnson left its Neumora Therapeutics share count unchanged in Q2 2026.
Neumora Therapeutics made up 0.39% of Johnson & Johnson's portfolio in Q2 2026, its #12 holding.
Johnson & Johnson first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
Johnson & Johnson's Neumora Therapeutics position peaked at $31.5M in Q4 2023.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.